Profound Medical Corp.
No SEC Form 4 filings for $PROF in the last 30 days.
See all $PROF insider activity →Profound Medical (PROF) anticipates Q3 revenue of $9.8M-$10.0M, a 85%-89% YoY and 292%-300% QoQ increase, surpassing estimates by 45%-47%. Gross margin is expected to exceed 70%.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) reported preliminary Q3 2026 revenue of $9.8M-$10.0M, up 85%-89% YoY and 292%-300% QoQ. This exceeds analyst estimates by 45%-47%. Gross margin is expected to exceed 70%. The company will release full results on November 5, 2026.
Profound Medical Corp. (PROF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device c
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning PROF (Profound Medical Corp.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent PROF coverage spans earnings, corporate actions and financial news.
Guidance beat may lift the stock as investors price in higher revenue expectations.
Preliminary revenue guidance well above expectations should lift the stock.
Leadership change may enhance execution and growth strategy, modest upside potential.
Near-doubling suggests a catalyst or momentum trade, but the article does not specify what drove it.
New real-time iMRI treatment delivery software could improve throughput and adoption, but the article provides no financial targets or adoption metrics.
AlphAI scores every news story that mentions PROF with an AI model for sentiment and relevance, and aggregates insider trades from Profound Medical Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Profound Medical (PROF) anticipates Q3 revenue of $9.8M-$10.0M, a 85%-89% YoY and 292%-300% QoQ increase, surpassing estimates by 45%-47%. Gross margin is expected to exceed 70%.
1 min readProfound Medical Corp. (NASDAQ:PROF; TSX:PRN) reported preliminary Q3 2026 revenue of $9.8M-$10.0M, up 85%-89% YoY and 292%-300% QoQ. This exceeds analyst estimates by 45%-47%. Gross margin is expected to exceed 70%. The company will release full results on November 5, 2026.
2 min readProfound Medical Corp. (PROF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device c
2 min readThe Dow fell 87.36 points, or 0.16%, to 53,372.42 Tuesday as oil rose above $90 amid Iran tension concerns. Home Depot reported fiscal Q2 sales of $47.86B vs ~$47.27B expected and adjusted EPS of $4.92 vs $4.73, reaffirming FY guidance. Memory chip stocks slid; other movers included Xos and Profusa.
6 min readProfound Medical Corp. (NASDAQ:PROF, TSX:PRN) announced the launch of new real-time interventional MRI software, its latest Treatment Delivery Consol (TDC). The company says the most recent TDC software could help customers reach up to 6 TULSA Procedures per system per day, outlining a roadmap toward full “TULSA Days.”
2 min readProfound Medical Corp. (PROF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Profound Medical Announces Management Change TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMR
2 min readProfound Medical Corp. (NASDAQ:PROF; TSX:PRN) said Matthew Sobczyk was promoted from Corporate Controller to Interim CFO, effective immediately, replacing Rashed Dewan, who stepped down as CFO and will stay on a short-term consulting contract. The company cited Sobczyk’s tenure since 2020 and aims to maintain continuity while executing its growth strategy for TULSA technology.
2 min readProfound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, c
6 min readProfound Medical Corp. (NASDAQ:PROF, TSX:PRN) will report its Q2 2026 financial results after market close on Aug. 6, 2026, and hold a conference call at 4:30 p.m. ET to discuss results and business updates, according to the company. The release also describes its iMRI platforms TULSA-PRO and Sonalleve and related regulatory clearances.
2 min readProfound Medical Corp. (NASDAQ:PROF, TSX:PRN) said its MRI-guided, AI-powered TULSA-PRO incisionless prostate ablation will be featured at SRS2026 in Fort Lauderdale, July 23-26, with multiple physician presentations on registry and CAPTAIN trial outcomes. Profound also plans an investor session July 22 with Stifel and Wells Fargo analysts.
2 min read
